Clinical Operations
Clinical Project ManagementStudy Monitoring and Site ManagementTrial Master File and Document ManagementQuality and Vendor Management SystemsStudy DocumentsRegulatory Affairs
Regulatory StrategyRegulatory WritingAgency Communications and SubmissionsDocument Editorial, QC and SubmissionQC, Review and RedactionLegal RepresentationPharmacovigilanceILAP SubmissionsMedical Communications
Publication PlanningStrategic CommunicationsScientific CommunicationsMedical EducationMedical IllustrationGrant Applications and Project PartnershipNiche serves as Legal Representation for Sorriso in the UK. Routine activities include:
Sorriso Pharmaceuticals is a biotechnology company focused on developing innovative therapeutics aimed at addressing unmet medical needs in various therapeutic areas, including oncology, neurology and infectious diseases. Founded in 2020, Sorriso has established a strong pipeline of drug candidates that leverage cutting-edge research and advanced drug delivery systems. With a commitment to enhancing patient outcomes, the company collaborates with leading academic institutions and industry partners to bring new therapies from the lab to clinical application. Sorriso's dedication to scientific excellence and patient care positions it as a significant player in the pharmaceutical landscape, striving to improve the quality of life for patients worldwide.
Sorriso first approached NST in 2023 as they were looking to conduct their first Phase I trial in the UK. Sorriso needed a knowledgeable and experienced organisation with a history working with Phase I studies in the UK. NST have provided Legal Representation for the duration of the Phase 1 First-in-Human study. During the project, services included regular study progress meetings to keep up to date with the study, reviewing monitoring reports and protocol amendments, filing study-specific documents, reviewing SAE reports and reviewing agency communications. Throughout the project, NST developed a good working relationship thanks to clear and efficient communication.